REGOLA, FRANCESCA
 Distribuzione geografica
Continente #
NA - Nord America 414
EU - Europa 245
AS - Asia 84
OC - Oceania 4
AF - Africa 2
SA - Sud America 2
Totale 751
Nazione #
US - Stati Uniti d'America 413
DE - Germania 60
IT - Italia 57
CN - Cina 31
HK - Hong Kong 30
UA - Ucraina 30
FI - Finlandia 29
GB - Regno Unito 23
SG - Singapore 16
IE - Irlanda 13
RU - Federazione Russa 10
MK - Macedonia 7
FR - Francia 6
GR - Grecia 4
AU - Australia 3
PH - Filippine 2
SA - Arabia Saudita 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BR - Brasile 1
CA - Canada 1
CH - Svizzera 1
CI - Costa d'Avorio 1
ES - Italia 1
JO - Giordania 1
JP - Giappone 1
NL - Olanda 1
NZ - Nuova Zelanda 1
PE - Perù 1
SE - Svezia 1
TR - Turchia 1
UG - Uganda 1
Totale 751
Città #
Fairfield 65
Ashburn 48
Chandler 30
Hong Kong 30
Helsinki 27
Houston 26
Jacksonville 25
Princeton 25
Woodbridge 23
Cambridge 22
Wilmington 22
Seattle 19
New York 18
Ann Arbor 13
Dublin 13
Brescia 10
Singapore 9
Beijing 8
San Diego 7
Bergamo 6
Munich 5
Shanghai 5
Bosio 4
Des Moines 4
Changsha 3
Duncan 3
Melbourne 3
Redwood City 3
Rome 3
Skopje 3
Cosenza 2
Haikou 2
Khobar 2
Lappeenranta 2
Lodi 2
London 2
Los Angeles 2
Motta Baluffi 2
Mountain View 2
Nanchang 2
Nürnberg 2
Shenyang 2
Whitley Bay 2
Abidjan 1
Amman 1
Amsterdam 1
Athens 1
Auckland 1
Bari 1
Boardman 1
Cagayan de Oro 1
Chicago 1
Corridonia 1
Falkenstein 1
Forlì 1
Genova 1
Gorle 1
Hebei 1
Jiaxing 1
Kunming 1
Lanzhou 1
Lima 1
Madrid 1
Markham 1
Milan 1
Mount Carmel 1
Nanjing 1
Orange 1
Prescot 1
Rivoli 1
San Francisco 1
Soncino 1
Southwark 1
Taiyuan 1
Torino 1
Washington 1
Yurovka 1
Zhengzhou 1
Totale 543
Nome #
Effector T-cells are expanded in systemic lupus erythematosus patients with high disease activity and damage indexes 121
Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab 110
COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study 102
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy 79
Circulating follicular helper T cells (CD4+CXCR5+ICOS+) decrease in patients with rheumatoid arthritis treated with abatacept 77
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting 51
Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients 49
Can we use NOACS in APS? 37
Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy. 36
CXCL-13 serum levels in patients with rheumatoid arthritis treated with abatacept 31
Novel Targets for Drug Use in Eosinophilic Granulomatosis With Polyangiitis 18
Novel Therapies in Takayasu Arteritis. 18
Tapering belimumab in patients with systemic lupus erythematosus: a single-centre experience 15
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort 13
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study-Joint and Skin (BeRLiSS-JS) 8
Pregnancy in antiphospholipid syndrome: what should a rheumatologist know? 7
Totale 772
Categoria #
all - tutte 5.604
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.604


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020121 0 6 7 14 10 16 14 12 13 13 5 11
2020/2021180 7 27 13 23 14 13 7 12 16 25 15 8
2021/2022133 9 16 10 4 4 6 5 11 7 15 21 25
2022/202393 15 1 3 5 10 29 0 10 11 0 6 3
2023/2024162 13 3 21 14 5 30 3 16 35 1 5 16
2024/202520 7 13 0 0 0 0 0 0 0 0 0 0
Totale 772